- Home
- ACIU vs LWLG Comparison
ACIU vs LWLG Comparison
Compare ACIU & LWLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- LWLG
- Stock Information
- Founded
- ACIU 2003
- LWLG 1991
- Country
- ACIU Switzerland
- LWLG United States
- Employees
- ACIU N/A
- LWLG N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- LWLG Containers/Packaging
- Sector
- ACIU Health Care
- LWLG Industrials
- Exchange
- ACIU Nasdaq
- LWLG Nasdaq
- Market Cap
- ACIU 294.9M
- LWLG 286.4M
- IPO Year
- ACIU 2016
- LWLG N/A
- Fundamental
- Price
- ACIU $2.65
- LWLG $1.95
- Analyst Decision
- ACIU Strong Buy
- LWLG
- Analyst Count
- ACIU 2
- LWLG 0
- Target Price
- ACIU $12.00
- LWLG N/A
- AVG Volume (30 Days)
- ACIU 147.0K
- LWLG 935.1K
- Earning Date
- ACIU 03-13-2025
- LWLG 02-27-2025
- Dividend Yield
- ACIU N/A
- LWLG N/A
- EPS Growth
- ACIU N/A
- LWLG N/A
- EPS
- ACIU N/A
- LWLG N/A
- Revenue
- ACIU $48,505,404.00
- LWLG $113,190.00
- Revenue This Year
- ACIU $86.72
- LWLG N/A
- Revenue Next Year
- ACIU $118.28
- LWLG N/A
- P/E Ratio
- ACIU N/A
- LWLG N/A
- Revenue Growth
- ACIU 4097200.00
- LWLG N/A
- 52 Week Low
- ACIU $2.25
- LWLG $1.68
- 52 Week High
- ACIU $4.98
- LWLG $5.30
- Technical
- Relative Strength Index (RSI)
- ACIU 39.10
- LWLG 42.30
- Support Level
- ACIU $2.56
- LWLG $1.81
- Resistance Level
- ACIU $2.83
- LWLG $2.58
- Average True Range (ATR)
- ACIU 0.16
- LWLG 0.18
- MACD
- ACIU -0.00
- LWLG 0.00
- Stochastic Oscillator
- ACIU 16.85
- LWLG 30.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About LWLG Lightwave Logic Inc.
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.